{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:29:48Z","timestamp":1760142588137,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.biopha.2014.12.006","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T20:16:54Z","timestamp":1418415414000},"page":"233-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Raltegravir-based therapy in a cohort of HIV\/HCV co-infected individuals"],"prefix":"10.1016","volume":"69","author":[{"given":"L.","family":"Taramasso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.V.","family":"De Socio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Menzaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Orofino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Passerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Franzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dentone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.M.","family":"Celesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Penco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Libertone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Quirino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2014.12.006_bib0005","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1473-3099(13)70093-8","article-title":"Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials","volume":"13","author":"Eron","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.biopha.2014.12.006_bib0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/cid\/cir510","article-title":"Long-term treatment with raltegravir or efavirenz combined with tenofovir\/emtricitabine for treatment-naive human Immunodeficiency virus-1-infected patients: 156-week results from STARTMRK","volume":"53","author":"Rockstroh","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.biopha.2014.12.006_bib0015","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1097\/QAD.0b013e32835aa141","article-title":"Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study","volume":"26","author":"Madeddu","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2014.12.006_bib0020","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/COH.0b013e3282f11906","article-title":"The burden of HIV and hepatitis C virus coinfection","volume":"2","author":"Puoti","year":"2007","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.biopha.2014.12.006_bib0025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3851\/IMP2738","article-title":"Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and\/or C","volume":"19","author":"Hurt","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.biopha.2014.12.006_bib0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dkp446","article-title":"Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C","volume":"65","author":"Vispo","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.biopha.2014.12.006_bib0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jac\/dks341","article-title":"Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection","volume":"68","author":"Weimer","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.biopha.2014.12.006_bib0040","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/jac\/dkr083","article-title":"Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C","volume":"66","author":"Mac\u00edas","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.biopha.2014.12.006_bib0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1468-1293.2011.00933.x","article-title":"Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and\/or C virus coinfection","volume":"13","author":"Rockstroh","year":"2012","journal-title":"HIV Med"},{"key":"10.1016\/j.biopha.2014.12.006_bib0050","unstructured":"Italian Coordinators for the Study of Allergies and HIV Infection. https:\/\/www.cisai.info\/new\/index.html [1\/12\/2014, date last accessed]."},{"year":"2004","series-title":"Division of aids table for grading the severity of adult and pediatric adverse events version 1. 0","key":"10.1016\/j.biopha.2014.12.006_bib0055"},{"key":"10.1016\/j.biopha.2014.12.006_bib0060","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep.24013","article-title":"Non-invasive assessment of liver fibrosis","volume":"53","author":"Mart\u00ednez","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2014.12.006_bib0065","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jvh.12224","article-title":"The validity of serum markers for fibrosis staging in chronic hepatitis B and C","volume":"21","author":"Li","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.biopha.2014.12.006_bib0070","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jinf.2014.04.005","article-title":"A switch to RAltegravir improves antiretroviral associated hepatotoxicity in individuals co-infected with HIV and hepatitis C","volume":"69","author":"Cevik","year":"2014","journal-title":"J Infect"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332214002017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332214002017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:57:00Z","timestamp":1760093820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332214002017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":14,"alternative-id":["S0753332214002017"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2014.12.006","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Raltegravir-based therapy in a cohort of HIV\/HCV co-infected individuals","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2014.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}